Advanced Enzyme Technologies Ltd.
NSE: ADVENZYMES · Healthcare
Sector
Healthcare
Size band
Small cap
Market cap
3,147cr
P/E
26.1
ROE
17%
Dividend yield
1.8%
No price is shown on this page, live or delayed. It records what management said on the earnings call, and the company’s filings.
Measured against
Peer set
Pharmaceuticals & Drugs · largest 12 of 82 measured at Q1 FY27 · financials via Screener| Company | Operating margin | Revenue growth |
|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 29.0% | 10.5% |
| Divi's Laboratories Ltd. | 41.0% | 27.8% |
| Torrent Pharmaceuticals Ltd. | 34.0% | 54.8% |
| Lupin Ltd. | 30.0% | 32.1% |
| Dr. Reddy's Laboratories Ltd. | 11.0% | −5.5% |
| Cipla Ltd. | 17.0% | 2.3% |
| Zydus Lifesciences Ltd. | 24.0% | 22.0% |
| Mankind Pharma Ltd. | 26.0% | 12.9% |
| Aurobindo Pharma Ltd. | 21.0% | 16.3% |
| Torrent Power Ltd. | 19.0% | 2.8% |
| Alkem Laboratories Ltd. | 20.0% | 10.9% |
| Advanced Enzyme Technologies Ltd. | 27.0% | 2.2% |
What management said
8 statements on recordEarnings call · Q1 FY27 / quarter ended June 30, 2026 · 18 Aug 2026
- Revenue growth→double digits· FY27 / this year
“As of now, we think we should be able to grow in double digits.”
- Revenue growth→the kind of growth numbers which we have shared with you in past· FY27 / as the year progresses
“As we progress, we are confident that we shall be able to achieve the kind of growth numbers which we have shared with you in past.”
- U.S. business growth→8-10% of growth· at this juncture
“Many such issues are being addressed, and kind of the growth we can expect is, as we always say, U.S., we don't expect at least at this juncture beyond 8-10% of growth.”
- U.S. business growth→about 8% or so· by the end of the year
“As we progress, we will get more clarity, and I think we expect that we shall be having a better growth in the coming quarters. I think by the end of the year, it should be about 8% or so.”
- EBITDA margin→about 30% of EBITDA· rest of the year / full year
“Yes. We expect that it shall come back to the normal level of about 30% of EBITDA.”
- EBITDA margin→30-32% of EBITDA margin
“But as of now, we will just like to continue that we will be having a 30-32% of EBITDA margin, and that is what we are saying.”
- Capex→INR 123 crores
“INR 123 crores, you rightly said that we have explained in the AGM, correct? This is what we are going to spend.”
- Capex split→about INR 20 crore is normal capital expenditure; INR 50 crores will go for R&D; balance is all about the growth only
“Out of this, I think INR 20 crore is normal capital expenditure. INR 50 crores will go for R&D, which is already under work in progress. Maybe it will become functional in the next quarter or so. Balance is all about the growth only.”
Taken from management commentary on the company’s earnings call and quoted verbatim. These are statements of intent made by the company, not forecasts by Bharatstox, and nothing here records whether they were met.
No broadcast calls recorded.
We log calls made about a company on business television — Zee Business, CNBC Awaaz and NDTV Profit — as they are stated on air. Nothing is on record for Advanced Enzyme Technologies Ltd..
Shareholding
change across 4 filings| Category | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Change |
|---|---|---|---|---|---|
| Promoters | 43.2 | 43.3 | 43.0 | 43.1 | +0.1 |
| Foreign institutions | 26.7 | 25.5 | 25.9 | 25.4 | +1.3 |
| Domestic institutions | 4.8 | 5.4 | 5.5 | 6.4 | −1.6 |
| Retail & others | 25.3 | 25.8 | 25.6 | 25.1 | +0.2 |
As filed with the exchange for the periods ending Sep 25 to Jun 26.
Filings
latest 25 of 195- Updates15 Oct 2026
- Updates12 Oct 2026
- Certificate under SEBI (Depositories and Participants) Regulations, 20189 Oct 2026
- Updates7 Oct 2026
- Updates29 Sept 2026
- Trading Window28 Sept 2026
- Daily Report pursuant to Regulation 18(i) of the Buyback Regulations regarding the Equity Shares bought back on September 23, 202623 Sept 2026
- Daily Report pursuant to Regulation 18(1) of the Buyback Regulations regarding the Equity Shares bought back on September 22, 202622 Sept 2026
- Daily Report pursuant to Regulation 18(i) of the Buyback Regulations regarding the Equity Shares bought back on September 21, 202621 Sept 2026
- Daily Report pursuant to Regulation 18(i) of the Buyback Regulations regarding the Equity Shares bought back on September 18, 2026.18 Sept 2026
- Intimation of receipt of revised request from a few promoter group members for reclassification from Promoter Group category to Public category shareholders under Regulation 31A of the ....17 Sept 2026
- General Updates17 Sept 2026
- Daily Report pursuant to Regulation 18(i) of the Buyback Regulations regarding the Equity Shares bought back on September 17, 202617 Sept 2026
- Daily Report pursuant to Regulation 18(i) of the Buyback Regulations regarding the Equity shares bought back on September 16, 202616 Sept 2026
- Daily Report pursuant to Regulation 18(i) of the Buyback Regulations regarding the Equity Shares bought back on September 15, 202615 Sept 2026
- Daily Report pursuant to Regulation 18(i) of the Buyback Regulations regarding the Equity Shares bought back on September 11, 202611 Sept 2026
- Daily Report pursuant to Regulation 18(1) of the Buyback Regulations regarding the Equity Shares bought back on September 10, 202610 Sept 2026
- Copy of Newspaper Publication10 Sept 2026
- Please find enclosed herewith newspaper publication regarding special window for transfer and dematerialization of physical shares.10 Sept 2026
- Daily Report pursuant to Regulation 18(i) of the Buyback Regulations regarding the Equity Shares bought back on September 09, 20269 Sept 2026
- Daily Report pursuant to Regulation 18(i) of the Buyback Regulations regarding the Equity Shares bought back on September 08, 20268 Sept 2026
- Updates8 Sept 2026
- Extinguishment of 825028 (Eight Lakh Twenty Five Thousand and Twenty Eight) fully paid-up Equity Shares of the face value of Rs. 2/- each (Rupees Two Only) of Advanced Enzyme Technologies ....8 Sept 2026
- Daily Report pursuant to Regulation 18(i) of the Buyback Regulations regarding the Equity Shares bought back on September 07, 20267 Sept 2026
- Daily Report pursuant to Regulation 18(i) of the Buyback Regulations regarding the Equity Shares bought back on September 04, 20264 Sept 2026
The 25 most recent of 195 filings we hold for ADVENZYMES, back to January 2024. Every filing, by day.
Disclaimer
Guidance is quoted from management commentary on quarterly earnings calls; the words are the company's own and the targets are theirs, not ours. Peer comparisons use quarterly financials sourced from Screener, with every company measured at the same fiscal quarter; the peer set is companies sharing the same industry classification, and comparisons are descriptive, not a ranking or a view. Filings are reproduced as companies filed them to the NSE and BSE; Bharatstox does not verify, endorse or comment on their contents. This page is for informational and educational purposes only and does not constitute investment advice, research, or a recommendation to buy or sell any security. Investing in securities markets is subject to market risks. Read all related documents carefully before investing.